Savara (SVRA)

• Market cap: $1.23B
• 1 day: -0.82%
• 5 days: -13.18%
• 1 month: 45.32%
• 3 months: 68.33%
• 6 months: 192.75%
• Year to date: 97.39%
• 1 year: 100.66%
• 5 years: 345.59%
• 10 years: -78.36%
• Sector: Healthcare
• Industry: Biotechnology

About: Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Employees: 59